TLSI official logo TLSI
TLSI 1-star rating from Upturn Advisory
TriSalus Life Sciences Inc. (TLSI) company logo

TriSalus Life Sciences Inc. (TLSI)

TriSalus Life Sciences Inc. (TLSI) 1-star rating from Upturn Advisory
$7.06
Last Close (24-hour delay)
Profit since last BUY9.12%
upturn advisory logo
Consider higher Upturn Star rating
BUY since 7 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/05/2025: TLSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

2 star rating from financial analysts

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $11.36

1 Year Target Price $11.36

Analysts Price Target For last 52 week
$11.36 Target price
52w Low $3.42
Current$7.06
52w High $7.32

Analysis of Past Performance

Type Stock
Historic Profit -23.06%
Avg. Invested days 45
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/05/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 352.75M USD
Price to earnings Ratio -
1Y Target Price 11.36
Price to earnings Ratio -
1Y Target Price 11.36
Volume (30-day avg) 8
Beta 0.43
52 Weeks Range 3.42 - 7.32
Updated Date 12/6/2025
52 Weeks Range 3.42 - 7.32
Updated Date 12/6/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.12

Earnings Date

Report Date 2025-11-13
When -
Estimate -0.165
Actual -0.96

Profitability

Profit Margin -98.45%
Operating Margin (TTM) -77.94%

Management Effectiveness

Return on Assets (TTM) -61.1%
Return on Equity (TTM) -496.21%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 364185035
Price to Sales(TTM) 8.77
Enterprise Value 364185035
Price to Sales(TTM) 8.77
Enterprise Value to Revenue 9.06
Enterprise Value to EBITDA -5.96
Shares Outstanding 49964311
Shares Floating 39539258
Shares Outstanding 49964311
Shares Floating 39539258
Percent Insiders 42.41
Percent Institutions 19.46

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc.(TLSI) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

TriSalus Life Sciences Inc. is a privately held company focused on developing novel therapeutics and drug delivery systems for various medical conditions. Information on its founding year and specific historical milestones is not readily available in public domain as it is a private entity. Its evolution is centered around advancing its proprietary technology platforms.

Company business area logo Core Business Areas

  • Therapeutic Development: Focuses on developing innovative drug candidates for unmet medical needs. This includes utilizing their proprietary drug delivery systems to enhance efficacy and reduce side effects.
  • Drug Delivery Systems: Development and application of advanced drug delivery technologies, such as their proprietary platform for targeted delivery and sustained release of therapeutic agents.

leadership logo Leadership and Structure

As a privately held company, detailed information about its leadership team and organizational structure is not publicly disclosed. Leadership is typically comprised of experienced professionals in the pharmaceutical and biotechnology sectors.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • Description: A novel drug delivery technology designed for targeted and controlled release of therapeutic agents. This platform aims to improve drug efficacy, reduce systemic toxicity, and enhance patient compliance. Specific details on market share, user numbers, or revenue are not publicly available due to its private status. Competitors in the drug delivery space include established pharmaceutical companies and specialized biotechnology firms offering various advanced delivery methods (e.g., liposomes, nanoparticles, long-acting injectables).
  • Product Name: TriSalus Proprietary Drug Delivery Platform

Market Dynamics

industry overview logo Industry Overview

TriSalus Life Sciences operates within the pharmaceutical and biotechnology sectors, specifically focusing on drug discovery, development, and advanced drug delivery systems. This industry is characterized by high R&D investment, long product development cycles, stringent regulatory requirements, and intense competition. Key trends include personalized medicine, biologics, and innovative delivery mechanisms.

Positioning

TriSalus Life Sciences positions itself as an innovator in drug delivery, aiming to differentiate its therapeutic candidates by leveraging its proprietary technology to improve existing treatments and address novel therapeutic targets. Its competitive advantage lies in its unique technological approach to drug delivery.

Total Addressable Market (TAM)

The TAM for TriSalus's potential products is vast, encompassing the global markets for various therapeutic areas it targets (e.g., oncology, infectious diseases, chronic conditions) and the market for advanced drug delivery technologies. The global drug delivery market alone is projected to reach hundreds of billions of dollars. TriSalus aims to capture a share of this market by offering differentiated solutions.

Upturn SWOT Analysis

Strengths

  • Proprietary and innovative drug delivery technology platform.
  • Potential for enhanced therapeutic efficacy and reduced side effects.
  • Experienced leadership in pharmaceutical R&D (assumed).
  • Focus on addressing unmet medical needs.

Weaknesses

  • As a private company, limited public financial transparency.
  • Long development timelines and high R&D costs inherent in drug development.
  • Dependence on successful clinical trial outcomes.
  • Need for significant capital investment for development and commercialization.

Opportunities

  • Growing demand for advanced drug delivery systems.
  • Partnership opportunities with larger pharmaceutical companies for co-development or licensing.
  • Expansion into new therapeutic areas.
  • Potential for out-licensing of its delivery technology.

Threats

  • Intense competition from established and emerging biotechnology companies.
  • Regulatory hurdles and the risk of trial failures.
  • Patent expirations and generic competition for related drugs.
  • Changes in healthcare policies and reimbursement landscapes.

Competitors and Market Share

Key competitor logo Key Competitors

  • Johnson & Johnson (JNJ)
  • Pfizer Inc. (PFE)
  • Merck & Co., Inc. (MRK)
  • Novartis AG (NVS)
  • Roche Holding AG (RHHBY)

Competitive Landscape

TriSalus Life Sciences Inc. operates in a highly competitive landscape dominated by large pharmaceutical and biotechnology companies with extensive R&D resources and established market presence. Its competitive advantages are its specialized focus on innovative drug delivery technology and its potential to develop differentiated therapies. However, it faces significant challenges in competing with the scale and established pipelines of larger players.

Growth Trajectory and Initiatives

Historical Growth: Growth trajectory for a private company is primarily driven by its success in R&D, securing funding, and achieving development milestones. Specific historical growth data is not public.

Future Projections: Future growth projections are speculative and would depend on the successful development and commercialization of its pipeline products and technologies. Analyst estimates are not publicly available.

Recent Initiatives: Specific recent strategic initiatives are not publicly disclosed but are likely focused on advancing its drug candidates through preclinical and clinical development, and potentially seeking strategic partnerships or funding rounds.

Summary

TriSalus Life Sciences Inc. is a promising private biotechnology company with a focus on advanced drug delivery systems. Its proprietary technology offers potential for improved therapeutic outcomes, a significant strength in a competitive market. However, as a private entity, its lack of financial transparency and the inherent risks of drug development are notable weaknesses. Capitalizing on the growing demand for innovative drug delivery and forging strategic partnerships are key opportunities, while regulatory hurdles and strong competition pose significant threats.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • General industry knowledge of pharmaceutical and biotechnology sectors.
  • Publicly available information on drug delivery technologies.
  • Hypothetical competitor data for illustrative purposes, as TriSalus is private.

Disclaimers:

This analysis is based on publicly available information and general industry knowledge. TriSalus Life Sciences Inc. is a privately held company, and therefore, detailed financial data and operational specifics are not publicly disclosed. Market share data for competitors is illustrative and based on broad industry segments. This information is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About TriSalus Life Sciences Inc.

Exchange NASDAQ
Headquaters Westminster, CO, United States
IPO Launch date 2023-08-10
CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A.
Sector Healthcare
Industry Medical Devices
Full time employees 110
Full time employees 110

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.